Diagnosis and treatment of bradykinin-mediated angioedema: Outcomes from an angioedema expert consensus meeting

International Archives of Allergy and Immunology

Volumn 165, Issue 2, 2014, Pages 119-127

  Craig, Timothy J ^a   Bernstein, Jonathan A ^b   Farkas, Henriette ^c   Bouillet, Laurence ^d   Boccon Gibod, Isabelle ^d  

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^b UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

^c SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

^d GRENOBLE UNIVERSITY HOSPITAL   (France)

Author keywords

Angioedema; C1 inhibitor; C1 esterase inhibitor; Hereditary angioedema; Treatment

Indexed keywords

BRADYKININ; COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C1S INHIBITOR; COMPLEMENT COMPONENT C4; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ECALLANTIDE; ICATIBANT;

ANGIONEUROTIC EDEMA; CONSENSUS; GENE MUTATION; GENETIC SCREENING; HUMAN; MULTICENTER STUDY (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; ANGIOEDEMA; ANGIOEDEMAS, HEREDITARY; CONSENSUS DEVELOPMENT; DIFFERENTIAL DIAGNOSIS; METABOLISM; TREATMENT OUTCOME;

ANGIOEDEMA; ANGIOEDEMAS, HEREDITARY; BRADYKININ; DIAGNOSIS, DIFFERENTIAL; HUMANS; TREATMENT OUTCOME;

EID: 84911499704     PISSN: 10182438     EISSN: 14230097     Source Type: Journal    
DOI: 10.1159/000368404     Document Type: Review

References (42)

1. Bork K, Steffensen I, Machnig T: Treatment with C1-esterase inhibitor concentrate in type I or II hereditary angioedema: a systematic literature review. Allergy Asthma Proc 2013; 34: 312-327.
2. Lang DM, Aberer W, Bernstein JA, Chng HH, Grumach AS, Hide M, Maurer M, Weber R, Zuraw B: International consensus on hereditary and acquired angioedema. Ann Allergy Asthma Immunol 2012; 109: 395-402.
3. Cicardi M, Aberer W, Banerji A, Bas M, Bernstein JA, Bork K, Caballero T, Farkas H, Grumach A, Kaplan AP, Riedl MA, Triggiani M, Zanichelli A, Zuraw B: Classification, diagnosis, and approach to treatment for angioedema: consensus report from the Hereditary Angioedema International Working Group. Allergy 2014; 69: 602-616.
4. Zuraw BL, Bork K, Binkley KE, Banerji A, Christiansen SC, Castaldo A, Kaplan A, Riedl M, Kirkpatrick C, Magerl M, Drouet C, Cicardi M: Hereditary angioedema with normal C1 inhibitor function: consensus of an international expert panel. Allergy Asthma Proc 2012; 33(suppl 1):S145-S156.
5. Vitrat-Hincky V, Francois P, Labarere J, Recule C, Stahl JP, Pavese P: Appropriateness of blood culture testing parameters in routine practice: results from a cross-sectional study. Eur J Clin Microbiol Infect Dis 2011; 30: 533-539.
6. Bork K, Wulff K, Hardt J, Witzke G, Staubach P: Hereditary angioedema caused by missense mutations in the factor XII gene: clinical features, trigger factors, and therapy. J Allergy Clin Immunol 2009; 124: 129-134.
7. Cichon S, Martin L, Hennies HC, Muller F, van Driessche K, Karpushova A, Stevens W, Colombo R, Renne T, Drouet C, Bork K, Nothen MM: Increased activity of coagulation factor XII (Hageman factor) causes hereditary angioedema type III. Am J Hum Genet 2006; 79: 1098-1104.
8. Dewald G, Bork K: Missense mutations in the coagulation factor XII (Hageman factor) gene in hereditary angioedema with normal C1 inhibitor. Biochem Biophys Res Commun 2006; 343: 1286-1289.
9. Bork K: Diagnosis and treatment of hereditary angioedema with normal C1 inhibitor. Allergy Asthma Clin Immunol 2010; 6: 15.
10. Farkas H, Varga L: Abstracts of the 8th C1- Inhibitor Deficiency Meeting, Budapest, Hungary. J Angioedema 2013; 1: 1-51.
11. Vitrat-Hincky V, Gompel A, Dumestre-Perard C, Boccon-Gibod I, Drouet C, Cesbron JY, Lunardi J, Massot C, Bouillet L: Type III hereditary angio-oedema: clinical and biological features in a French cohort. Allergy 2010; 65: 1331-1336.
12. Binkley KE: Factor XII mutations, estrogendependent inherited angioedema, and related conditions. Allergy Asthma Clin Immunol 2010; 6: 16.
13. Bork K, Gul D, Hardt J, Dewald G: Hereditary angioedema with normal C1 inhibitor: clinical symptoms and course. Am J Med 2007; 120: 987-992.
14. Kaplan A: Drug-induced angioedema. J Angioedema 2011; 1: 14-22.
15. Campo P, Fernandez TD, Canto G, Mayorga C: Angioedema induced by angiotensin-converting enzyme inhibitors. Curr Opin Allergy Clin Immunol 2013; 13: 337-344.
16. Mahmoudpour SH, Leusink M, van der Putten L, Terreehorst I, Asselbergs FW, de Boer A, Maitland-van der Zee AH: Pharmacogenetics of ACE inhibitor-induced angioedema and cough: a systematic review and metaanalysis. Pharmacogenomics 2013; 14: 249-260.
17. Cilia La Corte AL, Carter AM, Rice GI, Duan QL, Rouleau GA, Adam A, Grant PJ, Hooper NM: A functional XPNPEP2 promoter haplotype leads to reduced plasma aminopeptidase P and increased risk of ACE inhibitor-induced angioedema. Hum Mutat 2011; 32: 1326-1331.
18. Woodard-Grice AV, Lucisano AC, Byrd JB, Stone ER, Simmons WH, Brown NJ: Sex-dependent and race-dependent association of XPNPEP2 C-2399A polymorphism with angiotensin- converting enzyme inhibitor-associated angioedema. Pharmacogenet Genomics 2010; 20: 532-536.
19. Kostis JB, Packer M, Black HR, Schmieder R, Henry D, Levy E: Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment versus Enalapril (OCTAVE) trial. Am J Hypertens 2004; 17: 103-111.
20. Brown NJ, Byiers S, Carr D, Maldonado M, Warner BA: Dipeptidyl peptidase-IV inhibitor use associated with increased risk of ACE inhibitor-associated angioedema. Hypertension 2009; 54: 516-523.
21. Sabroe RA, Black AK: Angiotensin-converting enzyme (ACE) inhibitors and angio-oedema. Br J Dermatol 1997; 136: 153-158.
22. Caballero T, Baeza ML, Cabanas R, Campos A, Cimbollek S, Gomez-Traseira C, Gonzalez-Quevedo T, Guilarte M, Jurado-Palomo GJ, Larco JI, Lopez-Serrano MC, Lopez-Trascasa M, Marcos C, Munoz-Caro JM, Pedrosa M, Prior N, Rubio M, Sala-Cunill A: Consensus statement on the diagnosis, management, and treatment of angioedema mediated by bradykinin. Part I. Classification, epidemiology, pathophysiology, genetics, clinical symptoms, and diagnosis. J Investig Allergol Clin Immunol 2011; 21: 333-347.
23. Zingale LC, Castelli R, Zanichelli A, Cicardi M: Acquired deficiency of the inhibitor of the first complement component: presentation, diagnosis, course, and conventional management. Immunol Allergy Clin North Am 2006; 26: 669-690.
24. Castelli R, Zanichelli A, Cicardi M, Cugno M: Acquired C1-inhibitor deficiency and lymphoproliferative disorders: a tight relationship. Crit Rev Oncol Hematol 2013; 87: 323-332.
25. Cicardi M, Zanichelli A: Angioedema due to C1 inhibitor deficiency in 2010. Intern Emerg Med 2010; 5: 481-486.
26. Farkas H: Current pharmacotherapy of bradykinin- mediated angioedema. Expert Opin Pharmacother 2013; 14: 571-586.
27. Zanichelli A, Bova M, Coerezza A, Petraroli A, Triggiani M, Cicardi M: Icatibant treatment for acquired C1-inhibitor deficiency: a real-world observational study. Allergy 2012; 67: 1074-1077.
28. Clinical Trials: Evaluation of ecallantide for the acute treatment of angiotensin converting enzyme inhibitor induced angioedema. http:// clinicaltrials.gov/show/NCT01036659 (accessed August 4, 2014).
29. Clinical Trials: Effect of bradykinin receptor antagonism on ACE inhibitor-associated angioedema. http://clinicaltrials.gov/show/ NCT01574248 (accessed August 4, 2014).
30. Lumry WR: A report from ACAAI: highlights of presentations given at the 2012 Annual Meeting of the American College of Allergy, Asthma and Immunology (ACAAI). J Angioedema 2013; 1: 1-12 .
31. Nielsen EW, Gramstad S: Angioedema from angiotensin-converting enzyme (ACE) inhibitor treated with complement 1 (C1) inhibitor concentrate. Acta Anaesthesiol Scand 2006; 50: 120-122.
32. Clinical Trials: Randomized, double-blind, two arms, multicenter, phase III study of berinert for treatment of ACE induced angioedema. http://clinicaltrials.gov/show/NCT01843530 (accessed August 4, 2014).
33. Cicardi M, Zanichelli A: Acquired angioedema. Allergy Asthma Clin Immunol 2010; 6: 14.
34. Craig T, Aygoren-Pursun E, Bork K, Bowen T, Boysen H, Farkas H, Grumach A, Katelaris CH, Lockey R, Longhurst H, Lumry W, Magerl M, Martinez-Saguer I, Ritchie B, Nast A, Pawankar R, Zuraw B, Maurer M: WAO guideline for the management of hereditary angioedema. World Allergy Organ J 2012; 5: 182-199.
35. Bouillet L, Boccon-Gibod I, Ponard D, Drouet C, Cesbron JY, Dumestre-Perard C, Monnier N, Lunardi J, Massot C, Gompel A: Bradykinin receptor 2 antagonist (icatibant) for hereditary angioedema type III attacks. Ann Allergy Asthma Immunol 2009; 103: 448.
36. Boccon-Gibod I, Bouillet L: Safety and efficacy of icatibant self-administration for acute hereditary angioedema. Clin Exp Immunol 2012; 168: 303-307.
37. Warrier MR, Copilevitz CA, Dykewicz MS, Slavin RG: Fresh frozen plasma in the treatment of resistant angiotensin-converting enzyme inhibitor angioedema. Ann Allergy Asthma Immunol 2004; 92: 573-575.
38. Hassen GW, Kalantari H, Parraga M, Chirurgi R, Meletiche C, Chan C, Ciarlo J, Gazi F, Lobaito C, Tadayon S, Yemane S, Velez C: Fresh frozen plasma for progressive and refractory angiotensin-converting enzyme inhibitor- induced angioedema. J Emerg Med 2013; 44: 764-772.
39. Bas M, Greve J, Stelter K, Bier H, Stark T, Hoffmann TK, Kojda G: Therapeutic efficacy of icatibant in angioedema induced by angiotensin-converting enzyme inhibitors: a case series. Ann Emerg Med 2010; 56: 278-282.
40. Gallitelli M, Alzetta M: Icatibant: a novel approach to the treatment of angioedema related to the use of angiotensin-converting enzyme inhibitors. Am J Emerg Med 2012; 30: 1664.e1-2.
41. Bas M, Greve J, Hoffmann TK, Reshef A, Aberer W, Maurer M, Kivity S, Farkas H, Floccard B, Arcoleo F, Martin L, Sitkauskiene B, Bouillet L, Schmid-Grendelmeier P, Li H, Zanichelli A: Repeat treatment with icatibant for multiple hereditary angioedema attacks: FAST-2 open-label study. Allergy 2013; 68: 1452-1459.
42. Kaplan AP: Angioedema. World Allergy Organ J 2008; 1: 103-113.